Market Overview

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

Share:

The law firm of Kessler Topaz Meltzer & Check, LLP reminds ACADIA
Pharmaceuticals Inc. (NASDAQ:ACAD) ("ACADIA") investors that a
securities fraud class action lawsuit has been filed on behalf of
purchasers of ACADIA securities between April 29, 2016 and July 9,
2018
, inclusive (the "Class Period").

REMINDER: Investors who purchased ACADIA securities during the
Class Period may, no later than September 17, 2018,
seek to be appointed as a lead plaintiff representative of the class.
For additional information or to learn how to participate in this action
please visit
www.ktmc.com/acadia-pharmaceuticals-securities-class-action.

According to the complaint, ACADIA is purportedly a biopharmaceutical
company focused on the development and commercialization of medicines to
address central nervous system disorders. The company claims its lead
drug is NUPLAZID, which was approved by the U.S. Food and Drug
Administration ("FDA") on April 29, 2016 for the treatment of
hallucinations and delusions associated with Parkinson's disease
psychosis. ACADIA launched NUPLAZID in the U.S. in May 2016.

The Class Period commences on April 29, 2016, when ACADIA issued a press
release announcing that the FDA approved NUPLAZID for the treatment of
hallucinations and delusions associated with Parkinson's disease
psychosis. ACADIA further stated that "[t]he FDA approval of NUPLAZID
was based on data from the pivotal Phase III Study-020 and other
supportive studies, representing the largest research and development
program in Parkinson's disease psychosis to date."

The complaint alleges that, on April 9, 2018, CNN reported that
"[p]hysicians, medical researchers and other experts told CNN that they
worried that [NUPLAZID] had been approved too quickly, based on too
little evidence that it was safe or effective. And given these mounting
reports of deaths, they say that more needs to be done to assess
Nuplazid's true risks." Following this news, ACADIA's share price fell
$5.03 per share, or 23.4%, to close at $16.50 per share on April 9, 2018.

Then, on April 25, 2018, CNN reported that the FDA was re-examining the
safety of NUPLAZID. Following this news, ACADIA's share price fell $4.27
per share, or 21.9%, to close at $15.20 per share on April 25, 2018.

Finally, on July 9, 2018, the Southern Investigative Reporting
Foundation (the "SIRF") published a report entitled "Acadia
Pharmaceuticals: This Is Not a Pharmaceuticals Company." Therein, the
SIRF stated that "evidence is mounting that something is horribly wrong
with ACADIA's sole drug, NUPLAZID," and that "ACADIA has accomplished
its growth in ways that have attracted intense regulatory scrutiny for
other drug companies" including "dispensing wads of cash to doctors to
incentivize prescription writing and downplaying mounting reports of
patient deaths." Following this news, ACADIA's share price fell $1.21
per share, or 6.8%, to close at $16.63 per share on July 9, 2018.

The complaint alleges that throughout the Class Period, the defendants
failed to disclose that: (1) adverse events and safety concerns related
to NUPLAZID threatened the drug's initial and continuing FDA approval;
(2) ACADIA engaged in business practices likely to attract regulatory
scrutiny; and (3) as a result of the foregoing, the defendants'
statements about ACADIA's business, operations, and prospects, were
materially false and/or misleading and/or lacked a reasonable basis.

Investors who wish to discuss this securities fraud class action and
their legal options are encouraged to contact Kessler Topaz Meltzer &
Check, LLP (James Maro, Jr., Esq. or Adrienne Bell, Esq.) at (888)
299-7706 or at info@ktmc.com.

ACADIA investors may, no later
than September 17, 2018
, seek to be appointed as a lead
plaintiff representative of the class through Kessler Topaz Meltzer &
Check, or other counsel of their choice, or may choose to do nothing and
remain an absent class member.

A lead plaintiff is a representative party who acts on behalf of all
class members in directing the litigation. In order to be appointed as a
lead plaintiff, the Court must determine that the class member's claim
is typical of the claims of other class members, and that the class
member will adequately represent the class. Your ability to share in any
recovery is not affected by the decision of whether or not to serve as a
lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and
federal courts throughout the country involving securities fraud,
breaches of fiduciary duties and other violations of state and federal
law. Kessler Topaz Meltzer & Check is a driving force behind corporate
governance reform, and has recovered billions of dollars on behalf of
institutional and individual investors from the United States and around
the world. The firm represents investors, consumers and whistleblowers
(private citizens who report fraudulent practices against the government
and share in the recovery of government dollars). The complaint in this
action was not filed by Kessler Topaz Meltzer & Check. For more
information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

View Comments and Join the Discussion!